Current and emerging breast cancer biomarkers

Journal of Cancer Research and Therapeutics

Volumn 11, Issue 3, 2015, Pages 508-513

  Sana, Maryam ^a   Malik, Hassan Jameel ^a  

^a NATIONAL INSTITUTE FOR BIOTECHNOLOGY AND GENETIC ENGINEERING NIBGE   (Pakistan)

Author keywords

Biomarkers; breast cancer; individualized therapy; mutation; prognostic and predictive factors

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLIN D1; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; TUMOR MARKER; BRCA2 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

BREAST CANCER; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME 16Q; CHROMOSOME 17; CHROMOSOME 17Q; CHROMOSOME 18Q; CHROMOSOME 1Q; CHROMOSOME 20Q; CHROMOSOME 8P; CHROMOSOME 8Q; FEMALE; HUMAN; PERSONALIZED MEDICINE; PROTO ONCOGENE; REVIEW; TUMOR SUPPRESSOR GENE; BREAST NEOPLASMS; CHROMOSOME ABERRATION; GENETICS; PATHOLOGY;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CHROMOSOME ABERRATIONS; CYCLIN D1; CYCLIN E; FEMALE; HUMANS; RECEPTOR, ERBB-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84945139477     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.163698     Document Type: Review

References (57)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
2. Butt Z, Haider SF, Arif S, Khan MR, Ashfaq U, Shahbaz U, et al. Breast cancer risk factors: A comparison between pre-menopausal and post-menopausal women. Breast Cancer 2012;62:120-124.
3. Yasmeen F, Zaheer S. Functional time series models to estimate future age-specific breast cancer incidence rates for women in Karachi, Pakistan. J Health Sci 2014;2:213-21.
4. Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A. Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treat Rev 2012;38:698-707.
5. Ullah MF, Aatif M. The footprints of cancer development: Cancer biomarkers. Cancer Treat Rev 2009;35:193-200.
6. Cracowski JL. Towards prognostic biomarkers in pulmonary arterial hypertension. Eur Respir J 2012;39:799-801.
7. Tainsky MA. Genomic and proteomic biomarkers for cancer: A multitude of opportunities. BBA Rev Cancer 2009;1796:176-93.
8. Lee DS, Kim SH, Suh YJ, Kim S, Kim HK, Shim BY. Clinical implication of p53 overexpression in breast cancer patients younger than 50 years with a triple-negative subtype who undergo a modified radical mastectomy. Jpn J Clin Oncol 2011;41:854-66.
9. Hosoda M, Yamamoto M, Nakano K, Hatanaka KC, Takakuwa E, Hatanaka Y, et al. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre-and postmenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Res Treat 2014;144:249-61.
10. Lane DP, Brown CJ, Verma C, Cheok CF. New insights into p53 based therapy. Discov Med 2011;12:107-17.
11. Chen F, Wang W, El-Deiry WS. Current strategies to target p53 in cancer. Biochem Pharmacol 2010;80:724-30.
12. Smeenk L, Lohrum M. Behind the scenes: Unravelling the molecular mechanisms of p53 target gene selectivity (Review). Int J Oncol 2010;37:1061-70.
13. Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, et al. A global map of p53 transcription-factor binding sites in the human genome. Cell 2006;124:207-19.
14. Wright PE, Dyson HJ. Intrinsically disordered proteins in cellular signalling and regulation. Nat Rev Mol Cell Biol 2015;16:18-29.
15. Varna M, Bousquet G, Plassa LF, Bertheau P, Janin A. TP53 status and response to treatment in breast cancers. Biomed Res Int 2011;2011:1-9
16. Collavin L, Lunardi A, Del Sal G. p53-family proteins and their regulators: Hubs and spokes in tumor suppression. Cell Death Differ 2010;17:901-11.
17. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
18. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes. Oncogene 2007;26:2157-65.
19. Misek DE, Kim EH. Protein biomarkers for the early detection of breast cancer. Int J Proteomics 2011;2011:343582.
20. Gutierrez C, Schiff R. HER2: Biology, detection, and clinical implications. Arch Pathol Lab Med 2011;135:55-62.
21. Aratake J, Suzuki E, Uehiro N, Nishie M, Kawaguchi K, Sato F, et al. Trogocytosis of HER2 overexpressing human breast cancer cell lines may induce its dormancy without depending on HER family signal. Cancer Res 2014;74:1092.
22. Kaufmann R, Müller P, Hildenbrand G, Hausmann M, Cremer C. Analysis of Her2/neu membrane protein clusters in different types of breast cancer cells using localization microscopy. J Microsc 2011;242:46-54.
23. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: Current status and future perspectives. Nat Rev Clin Oncol 2012;9:16-32.
24. Faltus T, Yuan J, Zimmer B, Krämer A, Loibl S, Kaufmann M, et al. Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. Neoplasia 2004;6:786-95.
25. Melhem-Bertrandt A, Bojadzieva J, Ready KJ, Obeid E, Liu DD, Gutierrez-Barrera AM, et al. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer 2012;118:908-13.
26. de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): Survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol 2014;15:1137-46.
27. Murphy CG, Fornier M. HER2.positive breast cancer: Beyond trastuzumab. Oncology (Williston Park) 2010;24:410-5.
28. Metcalfe K, Lynch HT, Foulkes WD, Tung N, Kim-Sing C, Olopade OI, et al. Effect of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers. JAMA Oncol 2015;1:306-13.
29. Rosen EM, Fan S, Ma Y. BRCA1 regulation of transcription. Cancer Lett 2006;236:175-85.
30. O'Donovan PJ, Livingston DM. BRCA1 and BRCA2: Breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis 2010;31:961-7.
31. Haroun I, Graham T, Poll A, Sun P, Hill K, Weitzner E, et al. Reasons for risk-reducing mastectomy versus MRI-screening in a cohort of women at high hereditary risk of breast cancer. Breast 2011;20:254-8.
32. Narod SA. BRCA1 and BRCA2 in 2005. Discov Med 2005;5:50-4.
33. Ewald IP, Izetti P, Vargas FR, Moreira MA, Moreira AS, Moreira-Filho CA, et al. Prevalence of the BRCA1 founder mutation c. 5266dupin Brazilian individuals at-risk for the hereditary breast and ovarian cancer syndrome. Hered Cancer Clin Pract 2011;9:12.
34. Gabai-Kapara E, Lahad A, Kaufman B, Friedman E, Segev S, Renbaum P, et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci U S A 2014;111:14205-10.
35. Chen C, Opazo JC, Erez O, Uddin M, Santolaya-Forgas J, Goodman M, et al. The human progesterone receptor shows evidence of adaptive evolution associated with its ability to act as a transcription factor. Mol Phylogenet Evol 2008;47:637-49.
36. Gao X, Nawaz Z. Progesterone receptors . Animal models and cell signaling in breast cancer: Role of steroid receptor coactivators and corepressors of progesterone receptors in breast cancer. Breast Cancer Res 2002;4:182-6.
37. Anderson E, Clarke RB. Steroid receptors and cell cycle in normal mammary epithelium. J Mammary Gland Biol Neoplasia 2004;9:3-13.
38. Brisken C. Reply to is progesterone a neutral or protective factor for breast cancer? Nat Rev Cancer 2014;14:146.
39. Denkert C, von Minckwitz G. Reply to Ki67 in breast cancer: A useful prognostic marker! Ann Oncol 2014;25:542-3.
40. Saraste M, Sibbald PR, Wittinghofer A. The P-loop . A common motif in ATP. and GTP-binding proteins. Trends Biochem Sci 1990;15:430-4.
41. Dingwall C, Laskey RA. Nuclear targeting sequences . A consensus? Trends Biochem Sci 1991;16:478-81.
42. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki.67 in early breast cancer. J Clin Oncol 2005;23:7212-20.
43. Zarrouki B, Benterki I, Fontes G, Peyot ML, Seda O, Prentki M, et al. Epidermal growth factor receptor signaling promotes pancreatic s-cell proliferation in response to nutrient excess in rats through mTOR and FOXM1. Diabetes 2014;63:982-93.
44. Knutsvik G, Stefansson IM, Aziz S, Arnes J, Eide J, Collett K, et al. Evaluation of Ki67 expression across distinct categories of breast cancer specimens: A population-based study of matched surgical specimens, core needle biopsies and tissue microarrays. PLoS One 2014;9:e112121.
45. Abraham RT, VanArsdale T, Shields DV, Lee NV, Koehler M, Arndt K. Abstract SY34-03: Braking the cycle: Inhibition of the cyclin D-Cdk4/6 pathway in breast cancer. Cancer Res 2014;74 19 Supplement: SY34-03.
46. Reid RJ, Du X, DIttmar JC, Rayannavar V, Sunjevaric I, Maurer M, et al. A synthetic genetic interaction screen in yeast identifies Plk1 as a promising therapeutic target in cancer cells that overexpress Cks1b. Cancer Res 2014;74 19 Supplement: 5088.
47. Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene 1995;11:1005-11.
48. Hosokawa Y, Gadd M, Smith AP, Koerner FC, Schmidt EV, Arnold A. Cyclin D1 (PRAD1) alternative transcript b: Full-length cDNA cloning and expression in breast cancers. Cancer Lett 1997;113:123-30.
49. Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 2005;23:4215-24.
50. Dickson MA. Molecular pathways: CDK4 inhibitors for cancer therapy. Clin Cancer Res 2014;20:3379-83.
51. Koff A, Giordano A, Desai D, Yamashita K, Harper JW, Elledge S, et al. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science 1992;257:1689-94.
52. Hunt KK, Keyomarsi K. Cyclin E as a prognostic and predictive marker in breast cancer. Semin Cancer Biol 2005;15:319-26.
53. Willmarth NE, Albertson DG, Ethier SP. Chromosomal instability and lack of cyclin E regulation in hCdc4 mutant human breast cancer cells. Breast Cancer Res 2004;6:R531-9.
54. Ohtsubo M, Roberts JM. Cyclin-dependent regulation of G1 in mammalian fibroblasts. Science 1993;259:1908-12.
55. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M. Human cyclin E, a nuclear protein essential for the G1.to-S phase transition. Mol Cell Biol 1995;15:2612-24.
56. Sgambato A, Zhang YJ, Arber N, Hibshoosh H, Doki Y, Ciaparrone M, et al. Deregulated expression of p27(Kip1) in human breast cancers. Clin Cancer Res 1997;3:1879-87.
57. Rogers S, Gloss BS, Lee CS, Sergio CM, Dinger ME, Musgrove EA, et al. Cyclin E2 is the predominant E-cyclin associated with NPAT in breast cancer cells. Cell Div 2015;10:1.